Who are Extubation U's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Succinylcholine Chloride, Nicotine Patch + Nicotine Gum, Placebo Tablet and Nicotine Patch, NRT (NicoDerm CQ), bupropion + nicotine gum, Atracurium, TBW.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/extubation-u.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Extubation U — Competitive Intelligence Brief

Extubation U (Extubation U) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuromuscular blocking agent. Area: Anesthesiology.

marketed Neuromuscular blocking agent Nicotinic acetylcholine receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Extubation U (Extubation U) — Seganest. Extubation U is a neuromuscular blocking agent that facilitates endotracheal tube removal.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Extubation U TARGET	Extubation U	Seganest	marketed	Neuromuscular blocking agent	Nicotinic acetylcholine receptor
Succinylcholine Chloride	SUXAMETHONIUM	Novartis	marketed	Depolarizing Neuromuscular Blocker	Muscle-type nicotinic acetylcholine receptor	1952-01-01
Nicotine Patch + Nicotine Gum	Nicotine Patch + Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Placebo Tablet and Nicotine Patch	Placebo Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
NRT (NicoDerm CQ)	NRT (NicoDerm CQ)	University of California, San Francisco	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
bupropion + nicotine gum	bupropion + nicotine gum	University of Wisconsin, Madison	marketed	Combination smoking cessation therapy (antidepressant + nicotine replacement)	Norepinephrine transporter, dopamine transporter (bupropion); nicotinic acetylcholine receptors (nicotine)
Atracurium, TBW	Atracurium, TBW	St. Antonius Hospital	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuromuscular blocking agent class)

Galderma R&D · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Fondation Ophtalmologique Adolphe de Rothschild · 1 drug in this class
Allergan · 1 drug in this class
Seganest · 1 drug in this class
University of California, Los Angeles · 1 drug in this class
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Extubation U — Competitive Intelligence Brief. https://druglandscape.com/ci/extubation-u. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab